Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Torsten, Westermeier"'
Autor:
Torsten Westermeier, Juergen Weber, Leonard Oppenheimer, Kenneth Todd Moore, Christopher C. Nessel, Andrea Nadel, Xiang Sun, Sanjay Jalota, Nancy Cook-Bruns, Gary Peters, Paul Burton, Guohua Pan, Frank Misselwitz, Elisabeth Perzborn, Peter M DiBattiste, Troy C. Sarich, Lloyd Haskell, Scott D. Berkowitz, Anthonie W. A. Lensing, Dagmar Kubitza
Publikováno v:
Annals of the New York Academy of Sciences. 1291:42-55
The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis-mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ebfe774abb21c0c1d6343af1113aa95
https://doi.org/10.1111/nyas.12136
https://doi.org/10.1111/nyas.12136
Publikováno v:
Diabetes and Vascular Disease Research. 6:32-37
The STOP-NIDDM trial was an international, double-blind, placebo-controlled randomised study in people with impaired glucose tolerance (IGT). They were treated with an α-glucosidase inhibitor, acarbose, to prevent diabetes; the overall number needed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72100fccfa768a29962539fc77a042a3
https://doi.org/10.3132/dvdr.2009.006
https://doi.org/10.3132/dvdr.2009.006
Publikováno v:
Clinical Drug Investigation. 23:679-686
Multiple oral therapies are required long term for the majority of patients with type 2 diabetes mellitus to achieve acceptable glycaemic levels; alternatively, insulin therapy has to be initiated. This study investigated the addition of acarbose to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e47c649cb04e1ab89f7ab3cf279356da
https://doi.org/10.2165/00044011-200323100-00007
https://doi.org/10.2165/00044011-200323100-00007
Publikováno v:
Gastrointestinal Endoscopy. 45:349-353
Background: With the exception of esophageal perforations, complications of pneumatic dilation are incompletely defined. This study analyzes the incidence of all complications of this procedure and their impact on the patients' clinical course. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211d7e8d226dded9aa43fce0fe665578
https://doi.org/10.1016/s0016-5107(97)70142-1
https://doi.org/10.1016/s0016-5107(97)70142-1
Autor:
Troy C, Sarich, Gary, Peters, Scott D, Berkowitz, Frank, Misselwitz, Christopher C, Nessel, Paul, Burton, Nancy, Cook-Bruns, Anthonie W A, Lensing, Lloyd, Haskell, Elisabeth, Perzborn, Dagmar, Kubitza, Kenneth T, Moore, Sanjay, Jalota, Juergen, Weber, Guohua, Pan, Xiang, Sun, Torsten, Westermeier, Andrea, Nadel, Leonard, Oppenheimer, Peter M, DiBattiste
Publikováno v:
Annals of the New York Academy of Sciences. 1291
The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis-mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6985004b7641761590c4eb6257e4fe39
https://pubmed.ncbi.nlm.nih.gov/23701516
https://pubmed.ncbi.nlm.nih.gov/23701516
Autor:
Martin Homering, Torsten Westermeier, Michael Gent, Ajay K. Kakkar, Tiemo J. Bandel, Frank Misselwitz, Alexander G.G. Turpie, Michael R. Lassen, Scott D. Berkowitz, Bengt I. Eriksson
Publikováno v:
Thrombosis and haemostasis. 105(3)
SummaryFour phase III studies compared oral rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA or TKA). A pooled analysis of these studies compared the effect of rivar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c495d92380d401669a629c03c3c81402
https://pubmed.ncbi.nlm.nih.gov/21136019
https://pubmed.ncbi.nlm.nih.gov/21136019
Autor:
Thomas Evers, Torsten Westermeier, Jean-Louis Chiasson, Qing Qiao, Andreas Brückner, Walter Lehmacher, Jaakko Tuomilehto, Martin Hellmich, Jaana Lindström, Markku Peltonen
Publikováno v:
Diabetes research and clinical practice. 87(2)
Aims To develop a risk-score model, based on available clinical data to assess absolute risk of type 2 diabetes among people with impaired glucose tolerance (IGT). Methods Data from the study to prevent non-insulin dependent diabetes mellitus (STOP-N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3562a64e0c640b3764addd74f505fff
https://pubmed.ncbi.nlm.nih.gov/20022651
https://pubmed.ncbi.nlm.nih.gov/20022651
Autor:
Frank Misselwitz, Alexander G.G. Turpie, Scott Berkowitz, Tiemo J. Bandel, Torsten Westermeier, Michael R. Lassen, Ajay K. Kakkar, Michael Gent, Martin Homering, Bengt I. Eriksson
Publikováno v:
Chest. 136:144S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58b099cd9d650669b7cb78d130d81b6c
https://doi.org/10.1378/chest.136.4_meetingabstracts.144s-a
https://doi.org/10.1378/chest.136.4_meetingabstracts.144s-a
Autor:
Torsten Westermeier, Frank Misselwitz, Ajay K. Kakkar, Alexander G.G. Turpie, Martin Homering, Bengt I. Eriksson, Tiemo J. Bandel, Michael R. Lassen, Michael Gent
Publikováno v:
Blood. 112:1986-1986
RECORD is a pivotal clinical trial program investigating rivaroxaban – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism (VTE) following elective total hip and knee replacement (THR and TKR). The four multinationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17faa9394d6a45a1deab6f2908de1d25
https://doi.org/10.1182/blood.v112.11.1986.1986
https://doi.org/10.1182/blood.v112.11.1986.1986
Autor:
Michael Gent, Tiemo J. Bandel, Torsten Westermeier, Martin Homering, Ajay K. Kakkar, Alexander G.G. Turpie, Frank Misselwitz, Michael R. Lassen, Bengt I. Eriksson
Publikováno v:
Blood. 112:36-36
Four multinational, randomized, double-blind, double-dummy phase III studies (RECORD1, 2, 3 and 4) investigated the oral, direct Factor Xa inhibitor rivaroxaban for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e30eeb713c9ca49158540575ae749d81
https://doi.org/10.1182/blood.v112.11.36.36
https://doi.org/10.1182/blood.v112.11.36.36